ABSTRACTS Abstract Topics 1. Breast Cancer 2. Cervical Cancer 3. Diagnostics and Preinvasive Disease 4. Endometrial Cancer 5. Fertility / Pregnancy 6. Miscellaneous 7. Nursing 8. Ovarian Cancer 9. Palliative Care 10. Prevention of Gynaecologic Cancer 11. Quality of Life after Treatment 12. Translational Research 13. Trophoblastic Diseases 14. Vaginal and Vulvar Cancer Abstract submission opens January 2019 Abstract submission deadline May 3, 2019 KEY DATES Abstract submission opens January 2019 Abstract submission closes May 3, 2019 Registration opens January 2019 Early registration closes July 10, 2019 ESGO Congress November 2–5, 2019 CONGRESS VENUE MEGARON Athens International Conference Centre Address: Vass. Sofias & Kokkali, 11521 Athens, Greece www.maicc.gr For more information please see the website https://congress.esgo.org/ or contact ESGO 2019 congress secretariat at [email protected]. ATHENS, GREECE FIRST ANNOUNCEMENT
Transcript
ABSTRACTSAbstract Topics1. Breast Cancer2. Cervical Cancer3. Diagnostics and Preinvasive Disease4. Endometrial Cancer5. Fertility / Pregnancy6. Miscellaneous7. Nursing8. Ovarian Cancer9. Palliative Care10. Prevention of Gynaecologic Cancer11. Quality of Life after Treatment12. Translational Research13. Trophoblastic Diseases14. Vaginal and Vulvar Cancer
Abstract submission opens January 2019
Abstract submission deadline May 3, 2019
KEY DATES
Abstract submission opens January 2019
Abstract submission closes May 3, 2019
Registration opens January 2019
Early registration closes July 10, 2019
ESGO Congress November 2–5, 2019
CONGRESS VENUEMEGARONAthens International Conference CentreAddress: Vass. Sofias & Kokkali, 11521 Athens, Greecewww.maicc.gr
For more information please see the website https://congress.esgo.org/ or contact ESGO 2019 congress secretariat at [email protected].
OUTLINE OF ESGO 2019 PRELIMINARY SCIENTIFIC PROGRAMMEState of the Art Sessions• Early stage high risk endometrial cancer • Results of ESGO-ESMO ovarian cancer consensus • Prevention and screening • SIOPE-ESGO Guidelines on gynaecological cancers in adolescents • GCIG-ESGO Guidelines on rare gynaecological cancers• Quality indicators in cervical cancer surgery• Looking to the future of cervical cancer therapy• Immunotherapy• Indications for lymphadenectomy in ovarian, cervical and endometrial cancers
Debates• HIPEC in ovarian cancer: does it become a standard now or need to be
evaluated?• Radical hysterectomy, laparoscopy or open surgery?• Use of imaging in the preoperative workup of endometrial cancer
Parallel Sessions• Surgical staging of advanced cervical cancer• Advanced stage endometrial cancer• Risk reducing strategies in gynaecologic cancers • Mucinous ovarian carcinoma: multidisciplinary approaches • Stratifying patients for radical cytoreduction in advanced ovarian cancer • Diagnostic approaches to suspicious ovarian mass• Emerging pathways and targeted treatments in gynaecologic cancer • Platinum resistant: definition, treatment options and future perspectives• How to implement quality assurance in surgical procedures• Advances in breast cancer treatment• Accessibility and financial burden of novel therapies for gynae cancer• Genetic counseling in gynae cancer: how, when and by whom• How to manage patients with positive PA nodes? • How to tailor surveillance strategy in gynaecological tumour boards?• Environmental aspects, specifically nutritional, lifestyle factors
in gynaecological cancer • Uterine sarcoma• Genital tract microbiome and gynaecological cancers • Perioperative care• The past and the future of lymphedema in gynaecologic oncology• Genital reconstructive techniques and sexual functions • Advanced stage of vulvar cancer • Overview of assessments of pros and quality of life • FIGO classification: flaws and advances
• Do guidelines and recommendations impact management of uterine cancer patients?
• Oncogeriatry in gynaeologic cancer• Management of bleeding • Micrometastases • Out of the box procedures• Gestational trophoblastic disease• Psycho oncology and sexual health• ESTRO session: Advances in radiotherapy • ESO session: Ovarian cancer observatory• ENGOT session: Future trials - what shall be the next?
Tumour Boards• Ovarian cancer tumour board• Fertility sparing management tumour board• INCIP session: Cancer in pregnancy tumour board• ESP session: Molecular tumour board
Video Sessions• Robotic, laparoscopic or open sugery?• Debulking procedures
Workshops• Management of complications in surgery treatments: a multidisciplinary
approach• Upper abdominal debulking procedures • Bowel surgery for gynaecologists • Colposcopy workshop
Titles of sessions are subject of final confirmation
ABOUT ESGOESGO VisionOptimal prevention and care for all women in Europe with gynaecological cancers.
ESGO MissionTo improve the health and well-being of European women with gynaecological (genital and breast) cancers through prevention, excellence in care, high quality research and education.
SCIENTIFIC PROGRAMME COMMITTEENicole Concin, Austria (ESGO 2019 Scientific Committee Chair)Alexandros Rodolakis, Greece (ESGO 2019 Congress President)Denis Querleu, France (ESGO President)David Cibula, Czech Republic (ESGO Past President)Cristiana Sessa, Switzerland (ESGO Vice-President)Philipp Morice, France (ESGO President-Elect)
Anna Fagotti, ItalyAnnamaria Ferrero, ItalyChristina Fotopoulou, UKDimitrios Haidopoulos, GreecePawel Knapp, PolandDina Kurdiani, GeorgiaJonathan Ledermann, UKSandro Pignata, Italy (ENGOT Chair)Jordi Ponce, SpainMansoor Raza Mirza, DenmarkCagatay Taskiran, TurkeyNikolaos Thomakos, GreeceElzbieta Van Der Steen Banasik, The NetherlandsPauline Wimberger, GermanyKamil Zalewski, Poland (ENYGO Chair)
